Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX NASDAQ:HCM NASDAQ:IMVT NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$60.76+0.9%$58.33$1.16▼$14.10$58.49M-0.12189,291 shs196,285 shsHCMHUTCHMED$15.97+7.6%$16.37$11.51▼$21.50$2.79B0.4556,157 shs68,834 shsIMVTImmunovant$17.14+6.3%$16.31$12.72▼$34.47$2.99B0.451.33 million shs2.07 million shsTYRATyra Biosciences$12.65+4.2%$10.96$6.42▼$29.60$674.21M1.1219,947 shs230,201 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics-2.27%+0.40%-1.05%+20.33%+21.33%HCMHUTCHMED+7.61%+6.40%-10.88%+4.04%-8.32%IMVTImmunovant+6.33%+16.68%+7.39%+2.21%-44.15%TYRATyra Biosciences+4.20%-0.16%+14.69%+19.91%-40.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$60.76+0.9%$58.33$1.16▼$14.10$58.49M-0.12189,291 shs196,285 shsHCMHUTCHMED$15.97+7.6%$16.37$11.51▼$21.50$2.79B0.4556,157 shs68,834 shsIMVTImmunovant$17.14+6.3%$16.31$12.72▼$34.47$2.99B0.451.33 million shs2.07 million shsTYRATyra Biosciences$12.65+4.2%$10.96$6.42▼$29.60$674.21M1.1219,947 shs230,201 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics-2.27%+0.40%-1.05%+20.33%+21.33%HCMHUTCHMED+7.61%+6.40%-10.88%+4.04%-8.32%IMVTImmunovant+6.33%+16.68%+7.39%+2.21%-44.15%TYRATyra Biosciences+4.20%-0.16%+14.69%+19.91%-40.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/AHCMHUTCHMED 3.00Buy$28.0075.33% UpsideIMVTImmunovant 2.83Moderate Buy$33.6096.03% UpsideTYRATyra Biosciences 3.14Buy$31.43148.45% UpsideCurrent Analyst Ratings BreakdownLatest TYRA, HCM, GMTX, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/2/2025TYRATyra BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$35.008/22/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/11/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$17.00 ➝ $18.007/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $28.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold$18.007/1/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AHCMHUTCHMED$630.20M4.42$0.29 per share55.60$4.43 per share3.60IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ATYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AHCMHUTCHMED$37.73MN/A0.0010.94N/AN/AN/AN/AN/AIMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.78N/AN/AN/AN/A-31.22%-29.49%11/6/2025 (Estimated)Latest TYRA, HCM, GMTX, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TYRATyra Biosciences-$0.53-$0.47+$0.06-$0.47N/AN/A8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49HCMHUTCHMED0.054.654.51IMVTImmunovantN/A12.3212.32TYRATyra BiosciencesN/A21.9421.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%HCMHUTCHMED8.82%IMVTImmunovant47.08%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%HCMHUTCHMED3.60%IMVTImmunovant1.80%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableIMVTImmunovant120174.32 million171.18 millionOptionableTYRATyra Biosciences2053.30 million45.20 millionOptionableTYRA, HCM, GMTX, and IMVT HeadlinesRecent News About These CompaniesWe're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash WiselySeptember 6 at 2:06 AM | finance.yahoo.comTyra Biosciences, Inc. $TYRA Shares Sold by Ally Bridge Group NY LLCSeptember 5 at 6:54 AM | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Purchased by Vestal Point Capital LPSeptember 4 at 7:17 AM | marketbeat.comRaymond James Initiates Coverage of Tyra Biosciences (TYRA) with Strong Buy RecommendationSeptember 4 at 4:59 AM | msn.comTyra Biosciences management to meet with OppenheimerSeptember 4 at 4:59 AM | msn.comTyra Biosciences initiated with a Strong Buy at Raymond JamesSeptember 3 at 3:01 PM | msn.comWalleye Capital LLC Has $1.31 Million Stake in Tyra Biosciences, Inc. $TYRASeptember 1, 2025 | marketbeat.comAlphaQuest LLC Raises Stock Holdings in Tyra Biosciences, Inc. $TYRAAugust 31, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Earns Buy Rating from HC WainwrightAugust 24, 2025 | marketbeat.comTyra Biosciences initiates paediatric study for achondroplasia treatmentAugust 22, 2025 | finance.yahoo.comTyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric AchondroplasiaAugust 21, 2025 | prnewswire.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comTyra Biosciences Announces Participation at Upcoming Investor EventsAugust 20, 2025 | prnewswire.comDelveInsight Business Research, LLP: FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 20, 2025 | finanznachrichten.deFGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 19, 2025 | finance.yahoo.comWall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?August 19, 2025 | zacks.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Here's What HappenedAugust 17, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Releases Earnings Results, Beats Estimates By $0.06 EPSAugust 16, 2025 | marketbeat.comTyra Biosciences reports Q2 EPS (47c), consensus (51c)August 14, 2025 | msn.comTyra Biosciences Narrows Loss in Q2August 14, 2025 | aol.comATyra Biosciences Reports Second Quarter 2025 Financial Results and HighlightsAugust 14, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYRA, HCM, GMTX, and IMVT Company DescriptionsGemini Therapeutics NASDAQ:GMTX$60.76 +0.57 (+0.95%) As of 09/5/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.HUTCHMED NASDAQ:HCM$15.97 +1.13 (+7.61%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.98 +0.01 (+0.09%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$17.14 +1.02 (+6.33%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$17.23 +0.09 (+0.50%) As of 09/5/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Tyra Biosciences NASDAQ:TYRA$12.65 +0.51 (+4.20%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.66 +0.00 (+0.04%) As of 09/5/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
